Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 785 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Gene Expression Clear all

Conditions: Prematurity, Histologic Chorioamnionitis
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Not listed
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Foot Ulcers
Interventions: Electrohydraulic-generated shock wave, Sham device plus standard of care; Device
Lead sponsor: SANUWAVE, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 18
States / cities: Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 12 more

Conditions: Gingival Recession
Interventions: CelTx™, Free Gingival Graft; Biological · Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Cutaneous Melanoma
Interventions: Not listed
Lead sponsor: Castle Biosciences Incorporated; Industry
Eligibility: 16 Years and older
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 3
States / cities: Atlanta, Georgia • Louisville, Kentucky • St Louis, Missouri

Conditions: Kidney Cancer
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Up to 120 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL, L-MYC and N-MYC Amplified Solid Tumors, NSCLC With High or Low L-MYC or N-MYC Expression, HR-positive, HER2-negative Breast Cancer, Prostate Cancer
Interventions: Oral MRT-2359; Drug
Lead sponsor: Monte Rosa Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 13 more

Conditions: Metastatic Colorectal Cancer
Interventions: fluorouracil, leucovorin calcium, oxaliplatin, irinotecan hydrochloride, bevacizumab, cetuximab, capecitabine, mutation analysis, gene expression analysis, laboratory biomarker analysis, immunohistochemistry staining method, nucleic acid sequencing, protein expression analysis, polymerase chain reaction, DNA analysis; Drug · Biological · Genetic + 1 more
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breastfeeding, Dietary Intervention, Milk Expression, Breast
Interventions: Lactation Support and ABME, Lactation Support and meal plan, Lactation Support; Other
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Cancer
Interventions: MEDI-547; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Bethesda, Maryland • Detroit, Michigan

Conditions: Breast Cancer
Interventions: nab-paclitaxel, trastuzumab, Doxorubicin, cyclophosphamide, Growth Factor Support, Surgery; Drug · Biological · Procedure
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 2
States / cities: Hays, Kansas • Kansas City, Kansas

Conditions: Endometrial Receptivity, Ovarian Hyperstimulation Syndrome
Interventions: GnRH agonist, hCG; Drug
Lead sponsor: UConn Health; Other
Eligibility: 21 Years to 33 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Breastfeeding, Breastmilk Expression
Interventions: Pumping every 2 hours, breast pumping every 3 hours; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: Up to 28 Days
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Colon Cancer
Interventions: Not listed
Lead sponsor: Agendia; Industry
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 17
States / cities: Glendale, California • Laguna Hills, California • Long Beach, California + 13 more

Conditions: Glioblastoma, Recurrent Glioblastoma, Resectable Glioblastoma
Interventions: Biospecimen Collection, Magnetic Resonance Imaging, Medical Chart Review; Procedure · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Soft Tissue Sarcoma, Sts, Sarcoma,Soft Tissue
Interventions: ADI PEG20, Ifosfamide, Radiotherapy, Mesna; Drug · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer
Interventions: [18F]FluorThanatrace; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Atherosclerosis
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years to 100 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Pumping, Breast, Milk, Human, Infant, Very Low Birth Weight, Preterm Birth
Interventions: NICU Acquires MOM, Mother Provides MOM; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: Not listed
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Barrett's Esophagus, Gastroesophageal Reflux, Esophageal Adenocarcinoma
Interventions: Not listed
Lead sponsor: Midwest Biomedical Research; Other
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Metastatic Breast Cancer
Interventions: Abraxane, Carboplatin; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Anorexia Nervosa, Obsessive-compulsive Disorder
Interventions: Functional Magnetic Resonance Imaging; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 12 Years to 19 Years · Female only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Obesity, Pregnancy, Breastmilk Collection, Infant Overnutrition, Gestational Diabetes Mellitus (GDM)
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 0 Years to 45 Years
Enrollment: 2,050 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2031
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Oklahoma City, Oklahoma

Conditions: Inflammation, Oxidative Stress
Interventions: Diet zinc; Other
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Oakland, California

Conditions: Seaweed Associated Changes in Healthy Subjects
Interventions: Seaweed, Placebo, Placebo2; Other
Lead sponsor: University of South Carolina; Other
Eligibility: 45 Years to 68 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Columbia, South Carolina

Search by objective public record fields.

Infant Immune Response to Bacterial Infection

A Comparison of the dermaPACE® (Pulsed Acoustic Cellular Expression) Device in Conjunction With Standard of Care Versus Standard of Care Alone in the Treatment of Diabetic Foot Ulcers

Expression of Angiogenic Biomarkers During Healing of Intra-Oral Soft Tissue Engineered Grafts

5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results

Gene Expression in Normal Tissue and Tumor Tissue From Patients Who Have Undergone Surgery For Kidney Cancer

Study of Oral MRT-2359 in Selected Cancer Patients

Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Effect of Prenatal and Postnatal Intervention Strategies on Breastfeeding Outcomes in Women With Excessive Weight (Ready, Set, Nourish Study)

Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors

Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression

Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation

Pumping to Up Maternal Milk Production for Preterms

A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma

Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma

Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer

Identification of Genes Expressed in Atherosclerotic Plaque

Reducing Disparity in Receipt of Mother's Own Milk in Very Low Birth Weight Infants

Evaluation of MicroRNA Expression in Blood and Cytology for Detecting Barrett's Esophagus and Associated Neoplasia

Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer

Neural Links Between OCD and Anorexia

Maternal Obesity, Breast Milk Composition, and Infant Growth

An Evaluation of Zinc Status Biomarkers

Dietary Seaweed and Early Breast Cancer: A Randomized Trial